Ohio State Navbar

Directory

Yvonne Efebera, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-2268

Email: efebera.1@osu.edu

 

Current OSU Appointments

Assistant Professor, Hematology

Physician, FGP-Hematology

 

Biographical

Teaching and Mentoring Focus/Accomplishments Since 2010, I have been involved in teaching medical students, residents and fellows. I am a participant in the Clinical Assessment and Problem Solving (CAPS) longitudinal program, having two first year medical students for the first 2 years of medical school in her clinic monthly. Students learn how to perform complete physical exam, taking a complete history, doing vitals, and doing a brief visit exam (SOAP note). I am involved in having 3rd and 4th year medical students do monthly rotations in my clinic learning about diagnosis and treatment of multiple myeloma (MM), amyloidosis and learning the process of Blood and marrow transplant (BMT). Residents from all levels do monthly rotations, and fellows do 3 months blocks, all with the goal of enhancing student/residents/fellows education, communication with patients, diagnosis and treatments of patients with multiple myeloma, amyloidosis and BMT. I am involved in the first and second year medical students lecture series in MM and Amyloidosis and patient interview and discussions. I participate in resident’s lectures during the lecture series, presenting didactics with clinical presentations, diagnosis and managements of MM, amyloidosis and basics and principles of BMT. I have been a research mentor for 2 residents, 2 fellows and one medical student. This has resulted in 4 manuscript, one that has been published ( by former resident Neil Dunavin), 2 that has been submitted for publication (current fellow Benjamin Chu and former fellow Galena Salem) and the forth that is under review (current medical student Akshata Pandit) . Seven abstracts have also resulted from my mentorship, presented at American Society of Hematology (ASH), The American Society of Blood and Marrow Transplant, The International Myeloma Working Group (IMW, France), and the European Society of Blood and Marrow Transplantation meetings. Neil Dunavin, a former resident traveled with me to Paris, France to present his abstract at the IMW meeting. I have been an invited speaker at grand rounds at Scioto County medical Center, Medcentral Health Center and the Rheumatology division at Ohio State University (OSU), speaking on MM and amyloidosis and giving perspective on autologous transplantation for both. She is involved with nursing education and lecture series. Lectures have including understanding MM and BMT. I give local lectures to students and patients in different support groups (e.g. leukemia lymphoma society, multiple myeloma opportunities for research and education) in MM, amyloidosis and BMT.



Scholarship Focus/Accomplishments: Since joining Ohio State University in August 2009I have been actively involved in research. I currently have six active clinical trials three of which are investigator initiated. My first investigator initiated phase II study “evaluating the safety and efficacy of atorvastatin for the prophylaxis of acute graft-versus-host disease (GVHD) in patients with hematological malignancies undergoing HLA-matched sibling donor allogeneic hematopoeitic stem cell transplant (HSCT)” has completed accrual of 40 patients-donor pairs under two years as of January 31 2014. Patients are currently being followed for endpoint assessments. Correlative measurements including Cytokine analysis and immunomes are being conducted and will be compared to historic control patients who did not receive statin for allogeneic HSCT. The manuscript is in preparation and will be submitted to The New England Journal of Medicine or Journal of Clinical Oncology”. In the meantime I have presented abstracts from this study at ASH 2012 and ASBMT 2013. We hope to use the findings of this study to propose a comparison study using standard controls from the Center for International Blood and marrow transplant (CIBMTR) data. This work also holds great promise in that it could lead to a Phase III study through the BMT/CTN collaborative group evaluating standard GVHD prophylaxis with and without atorvastatin in patients undergoing HSCT and could also extend to solid organ transplantation. The second Investigator Initiated study “Assessment of Micro-RNA’s in acute graft-versus-host-disease (aGVHD)” opened in April 2012, and has now accrued 240 patients who are undergoing allogeneic HSCT. Dr. Garzon and I proposed to prospectively evaluate the microRNA expression profile of adult patients undergoing allogeneic HSCT. Weekly samples up to day 100 of HSCT are being collected with extraction of serum, plasma and mononuclear cells. This study holds great promise in investigating the role of microRNAs in the pathogenesis of acute GVHD, which may lead to the development of safer and more effective GVHD prophylactic and treatment strategies for HSCT patients. I currently have 3 abstracts, 2 presented at the European hematology Association (EHA 2013) and at ASH 2013 and one submitted to EHA 2014. The third Investigator initiated study “phase II study of CT-011( a program-death -1 inhibitor) with lenalidomide in relapse multiple myeloma” opened March 1, 2014 with cohort 1 completely filled by the first wk. A fourth Investigator initiated Study “ AR42 (a histone deacetylase) with pomalidomide in relapse and refractory multiple myeloma “ is in the protocol phase and will be partly sponsored by Celgene.



I was the local PI for the BMT/CTN 0702 study “A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma” that closed 6 months ahead of schedule due to OSU being the lead accruing center of 60 patients. In addition, I am the local PI on the soon to open adopted BMT/CTN study “A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age”; The ALLIANCE A061202 study “A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy”; and a first in man study “A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001(a novel immunomodulatory compound that induces an antigen-specific immune tolerance and CD4+Foxp3+ regulatory T-cell proliferation) in Patients Undergoing Allogeneic HSCT” that has completed accrual with OSU accruing the most and is now at the expansion phase. In addition I am the local PI of two acute GVHD refractory studies.



I have an ALLIANCE sponsored study as co-PI with Dr. Jacob Laubach (Dana Farber) “phase II study with Ibrutinib with lenalidomide in relapse multiple myeloma” that has been supported by Celgene and pharmacyclics, and hopefully to open fall 2014. I am on the protocol team for the next BMT/CTN study for allogeneic SCT in MM “ BMT CTN 1302 A Multicenter Phase II, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma”; and the BMT/CTN sponsored “RESCUE” trial “RandomizEd trial of high dose melphalan with autologous Stem Cell transplant in patients with multiple myeloma relapsing after 1ry therapy Using carfilzomib based consolidation and maintenance”. Dr. Garzon and I are collaborating with the University of Michigan on a database and biorepository for aGVHD- The “Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository” which got IRB approval 3/31/14. The MAGIC Study will collect 500 patient samples a year for current and future studies on biomarkers for aGVHD.



I am the recipient of several grants: the NIH Loan repayment program for two of my Investigator initiated studies; the National Institute of Health Heart, Lung and Blood institute (NHLBI) R21 grant (with Dr. Garzon) for the study of biomarkers and MiRs in aGVHD; An American Cancer Society (ACS) grant for the CT-011 and lenalidomide study; A K12 institutional grant; and an institutional CCTS grant. I have applied for a pelotonia grant to assist with my AR42 +Pomalidomide study. A Program Project grant is planned to be submitted in May 2014 for the MAGIC study in collaboration with The University of Michigan. In addition I have applied for several grants including the NIH K23, ASBMT, ASH, CALGB, ASCO, and The Harold Amos Medical Faculty Development Program.



Service Focus/Accomplishments: I am nationally recognized for my work in MM and in BMT. I am the OSU representative on the multiple myeloma committee at the ALLIANCE (formerly CALGB). I am on the BMT/CTN committee for the BMT/CTN 0702 study end-point (see under Service). I am on the International Amyloidosis End-point/Adjudication Committee for Millenium-Takeda C16011 International amyloidosis study, and I am on the multiple myeloma research foundation committee and the GVHD committee for ASBMT and ASH. I have moderated oral abstract session at ASH in transplantation; a national Medical ED forum on clinical dialogue in myeloma and the role of transplant in the era of novel agents; and media Interview on update in research for Graft-versus-Host-Disease. I have contributed to the ASCO educational Book being first author on the topic “Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia: Who Should Be Transplanted in First Complete Remission”. In addition, I have been invited by Dr. Caligiuri to do a chapter on “Classification and clinical manifestations of lymphocyte and plasma cell disorders” on the 9th edition of Williams Hematology, and have received an invitation to speak and participate in an international forum on the “Annual Summit on Practical and Emerging Trends in Multiple Myeloma and chronic lymphocytic leukemia” in whistler, Canada. I review for several journals including BLOOD Journal, Cancer Journal, Clinical Advances in Hematology and Oncology, Biology of Blood and Marrow Transplantation, British Journal of Haematology, Bone Marrow Transplant and Leukemia and Lymphoma. Locally at OSU, I am a member of the Ethics Committee, the BMT translational research committee, the search committee for the director of palliative care, the Multiple Myeloma Opportunities for Research and Education (MMORE) committee and the chair of the BMT GVHD committee. I was a member of the medical Staff advisory committee for one year 2010-2011, and I’m involved in the interview process of medical students for the Internal Medicine residency program. I am currently enrolled in the Masters of Public Health program- to finish in December 2014. I have published 24 manuscripts with 10 being first or last author and 2 as second author.

SUMMARY: In Summary, in my first 4 years here on staff, I am happy to say that I have been productive in teaching, mentoring, research and service. My mentors Dr. Steven Devine, program director of the blood and marrow program at OSU, and Dr. John Byrd, director of the hematology program have been wonderful in providing me with the tools needed to succeed in academics. Meeting with Dr. Devine monthly has kept me focused and provided me with new ideas for new projects. I hope to continue in thus path with more prospective studies publication in higher impact journals.

Academic Advising

I was an ad hoc academic advisor to an OSU undergraduate student Selamawit Admasu, who spent time with me in the clinic and on the in-patient service. She is now a medical student at University of Kentucky College of Medicine. Part of my weekly tutorial of high school students is also spent on advising. I have been a research mentor for 2 residents, 2 fellows and one medical student. This has resulted in 4 manuscript, one that has been published ( by former resident Neil Dunavin), 2 that has been submitted for publication (current fellow Benjamin Chu and former fellow Galena Salem) and the forth that is under review (current medical student Akshata Pandit) . Seven abstracts have also resulted from my mentorship, presented at the American Society of Hematology (ASH), American Society of Blood and Marrow Transplantation (ASBMT), The International Myeloma Working Group (IMW), and the European Society of Blood and Marrow Transplantation meetings.

Academic Advising

2012 - present Akshata Pandit The Ohio State University. Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL Amyloidosis)
2013 - present Benjamin Chu The Ohio State University. Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome
2011 The Ohio State University.
2010 - 2012 Neil Dunavin The Ohio State University. Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma; Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study.
2011 - 2012 Selamawit Admasu The Ohio State University. Graduated 2013.
2011 - 2012 Joyce Habib The Ohio State University. Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation; Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma.
2010 - 2013 Galena Salem The Ohio State University. Graduated 2013. Lower Dose of Antithymocyte Globulin (ATG) decreases bacterial infection without Increasing Graft-vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant ( allo HSCT); 2.Busulfan, Cyclophosphamide, Etoposide is Not Superior to Carmustine, Etoposide, Cytarabine, Melphelan Conditioning Prior to Autologous Stem Cell Transplantation n Patients with Hodgkin Lymphoma & is Associated with increase toxicity
 

Certifications

2000 - present State of Ohio Medical Board: State Medical Board of Ohio
2002 - present Board Certified: American Board of Internal Medicine
2008 - present Board Certified: American Board of Internal Medicine
 

Chapters in Books

Efebera YA, de Lima M.. "Hematopoietic Stem Cell Transplantaion for Acute Myelogenous Leukemia: Who should be Transplanted in First complete remission?.." In ASCO Educational Book-Category: Leukemia, Myelodysplasia, and Transplantation. -. Alexandria, VA: American Society for Clinical Oncology, January 2010.

 

Clinical Services

09/01/2009 HEM I In Patient Service (James Cancer Hospital, Hematology)
10/01/2009 BMT In Patient Service (James Cancer Hospital, Hematology)
10/01/2009 Multiple Myeloma Outpatient Clinic (2nd Floor James Cancer Hospital)
12/01/2011 HNP In Patient Service (James Cancer Hospital, Hematolgy)

Conferences

Efebera,Yvonne,A; Ahmadi,Tahamtan; Flies,Amanda; Sherr,David,H. "CD40 ligand activation alters B cell migration to secondary lymphoid organs.." In BLOOD. (November 2006). 279A-279A, abstract 935.

Tahamtan Ahmadi, Nathalie Weizmann, Yvonne Efebera, David Sherr.. "Primary antigen-specific B cells: A novel approach to cellular-based immunotherapy.." In BLOOD. (November 2006). 1061A-1062A, abstract 3717.

Rao Prabhala, Dheeraj Pelluru, Paola Neri, Mariateresa Fulciniti, James Driscoll, Song Weihua, Simona Blotta, Yu-Tzu Tai, Hiren Patel, Yvonne A. Efebera, Teru Hideshima, Dhaminder Chauhan, John F. Daley, Kenneth C. Anderson, Nikhil C. Munshi. "T(H)17 pathway and associated pro-inflammatory cytokines promote immune dysfunction in myeloma." In BLOOD. (November 2007). 1030A abstract 3517-.

Yvonne A. Efebera, Hagop M. Kantarjian, Borje Anderson, Sherry Pierce, Leandro De Padua Silva, Farhad Ravandi, Sergio A. Giralt, Gautam Borthakur, Richard Champlin, Marcos De Lima.. "Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CRI) Post Induction Chemotherapy: a Retrospective Case Control Study.." In BLOOD. (November 2008). 411, abstract 1125-.

Yvonne Efebera, Elizabeth Blanchard, Charles Allam, Andrew Han, Nikhil Munshi. "Complete Response to Thalidomide and Dexamethasone in a patient with Necrobiotic Xanthogranuloma (NXG) associated with Monoclonal Gammopathy of Uncertain Significance (MGUS)." In Blood. (November 2008). abstract 5210-.

Rao Prabhala, Dheeraj Pelluru, Paola Neri, Mariateresa Fulciniti, James Driscoll, Song Weihua, Simona Blotta, Yu-Tzu Tai, Hiren Patel, Yvonne A. Efebera, Teru Hideshima, Dhaminder Chauhan, John F. Daley, Kenneth C. Anderson, Nikhil C. Munshi.. "TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application.." In BLOOD. (November 2008). 945-946, abstract 2737.

Prabhala RH, Pelluru D, Fulciniti M, NanjappA P, Prabhala NS, Mitsiaties C, Lefkimmiatis K,Tai YT, Efebera YA, Daley JF, Anderson KC, Munshi NC. "IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma." In CLINICAL LYMPHOMA & MYELOMA. (February 2009). S159-S159.

Don Benson, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, Yvonne A Efebera, Megan K Smith, Carli N Greenfield, Pascale Andre, Patrick Squiban, Francois Romagne, Michael A. Caligiuri, and Steven M Devine.. "Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma." In Blood. (November 2009). abstract 4641-.

Rao H Prabhala, Yvonne A Efebera, Saem Lee, Andrew J Han, Dheeraj Pelluru, Puru Nanjappa, Samir Amin, Christine Pai, Irene Ghobrial, Robert L Schlossman, Jacob Laubach, Mariateresa Fulciniti, Paul Richardson, Kenneth C. Anderson, Nikhil C. Munshi.. "Lack of Response to Vaccination in MGUS and Stable Myeloma." In BLOOD. (November 2009). 734-735 abstract 1852.

Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A, Hosing C, Ledford M, Champlin R, Giralt S. "Impact of Pre-stem Cell Transplant Ferritin Levels on late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Outcomes." In Biology of Blood and Marrow Transplantation. (February 2009). 92-93, abstract 254.

Craig C Hofmeister, Don Benson, Yvonne A Efebera, Sherif Farag, Michael R. Grever. "Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma." In BLOOD. (November 2009). 1126 abstract 2884-.

Neil Dunavin, Joyce Habib, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Jr., Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera. "Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma." In BLOOD. (November 2010). 1466-1467 abstract 3564.

Joyce Habib, Neil Dunavin, MD, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Jr.,Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera. "Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study." In BLOOD. (November 2010). 575-576 abstract 1343.

Don M Benson, Jr, Courtney E Bakan, Swaminathan Padmanaban, Rafat Abonour, Attaya Suvannasankha, Sundar Jagannath, Ajai Chari, David Clever, Chidimma Kalu, Shauna Collins, Yousef Alghothani, Craig C. Hofmeister, Yvonne Efebera, Stephane Blanchet, Michael A. Caligiuri, Sherif Farag. "IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data." In BLOOD. (November 2010). 821: abstract 1966-.

Craig C. Hofmeister, Gisele Rieser, Mindy A Bowers, Lisa C Merritt, Carli N Greenfield, Yvonne A Efebera, Don M Benson, Jr., Steven M Devine, Janet S de Moor. "Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.." In BLOOD. (November 2010). 1557 abstract 3807-.

Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Abid Mohiuddin, Michal Rose, Caroline Behler, Andrew Han, Yvonne Efebera, Antoun Houranieh, Mary T. Brophy, Abraham Zimelman, Rao H Prabhala, Hussain I. Saba, Catherine Klein, Paulette Mehta, Teresa Hayes, David Roodman, Alan K. Lichtenstein. "Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities." In BLOOD. (November 2010). 1262-1263 abstract 3061.

Simrit Parmar, Gabriela Rondon, Peter F Thall, Roland Bassett, Marcos De Lima, Chitra M Hosing, Paolo Anderlini, Partow Kebriaei, Issa Khouri, Prasanth Ganesan, Yvonne A Efebera, Richard Champlin, and Sergio A Giralt.. "Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens." In BLOOD. (November 2011). 848, abstract 1944-.

Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Michal Rose, Abid Mohiuddin, Yvonne Efebera, Andrew Han, Antoun Houranieh, Abraham Zimelman, Mary T. Brophy, Rao Prabhala, Terrence Grady, Paulette Mehta, Teresa G Hayes, Sarvari Venkata Yellapragada, Caroline Behler, Catherine Klein, David Roodman, Alan K. Lichtenstein.. "Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities." In BLOOD. (November 2011). 1695-1696 abstract 3964.

20. McDonagh H, Falk W, Bingman A, Geyer S, Benson D, Efebera YA, Hofmeister C. "Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma." In BLOOD. (November 2012). abstract 4978-.

Salem G, Ruppert AS, Efebera Y, Elder P, Bingman A, Penza S, Andritsos L A, Devine SM. "Busulfan, cyclophosphamie, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2012). S246, abstract 115-.

Galena Salem, Neil Dunavin, Lai Wei, Pat Elder, Sam Penza, Kristie Blum, Pierlugi Porcu, Robert Baiocchi, Jeffrey Jones, Joseph Flynn, Leslie Andritsos, Steven M Devine, Beth Christian, Yvonne Efebera.. "Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity." In BONE MARROW TRANSPLANTATION. (April 2012). S84-S85, abstract 0365.

Andrew Stiff, Alberto Rocci, Craig C. Hofmeister, Paola Omedè, Susan Geyer, Sara Bringhen, Luciano Cascione, Anissa Bingman, Manuela Gambella, Federica Cavallo, Luciana De Luca, Jingwen Guan, Alessandra Larocca, Jacqueline Corry, Francesca Gay, Yvonne A Efebera, Uccello G, Don M. Benson, Jr., Tiffany Talabere, Kevin Murnan, Magarotto Valeria, Mario Boccadoro, Carlo M. Croce, Antonio Palumbo, Flavia Pichiorri. "miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients." In Blood. (November 2012). abstract 2921-.

Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson Jr. DM, Greenfield CN, Sell M, Devine SM.. "Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.." In Blood. (November 2012). abstract 3114-.

Jaglowski SM, Hofmeister C, Elder P, Penza S, Efebera YA, Benson Jr DM, Devine SM, Andritsos LA.. "The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma." In Blood. (November 2012). abstract 4286-.

Hofmeister CC, Bowers MA, Bingman A, Lozanski G, Baiocchi RA, Falk W, Benson DM, Jr., Efebera YA, Humphries K, Sell M, Greenfield CN, Lustberg ME, Vaughn JL, Earl CT, Geyer S, Devine SM. "Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma." In BLOOD. (November 2012). abstract 4460-.

Samantha M. Jaglowski, Sumithira Vasu, Susan Geyer, Anissa Bingman, Patrick Elder, Jianhua Yu, William Blum, Rebecca B Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Jr., Natarajan Muthusamy, Steven M. Devine, Leslie A Andritsos, Gerard Lozanski. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). abstract 1949-.

Mehdi Hamadani, Michael Craig, Scot Remick, Laura Gibson, William Petros, Jame Abraham, Aaron Cumpston, Pamela Bunner, Soumit Basu, William Tse, Carrie Hennelly, Sumi Vasu, Rebecca Klisovic, William Blum, Samantha Jaglowski, Don Benson, Leslie Andritsos, Sam Penza, Craig Hofmeister, Susan Geyer, Steven M. Devine, Yvonne Efebera. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). abstract 1939-.

Sumithira Vasu, Samantha M. Jaglowski, Susan Geyer, Anissa Bingman, Patrick Elder, Jianhua Yu, Leslie A Andritsos, William Blum, Rebecca B Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Jr, Natarajan Muthusamy, Steven M. Devine, Gerard Lozanski. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In BLOOD. (November 2012). abstract 4192-.

Douglas W. Sborov, Gerard Nuovo, Nita Williams, Andrew Stiff, Thomas Mace, Gregory Lesinski,. "A Phase 1 Trial of Reolysin Alone in Patients with Refractory or Relapsed Multiple Myeloma." In Blood. (November 2013). abstract 3208-.

Cohen JB, McBride A, Geyer S, Bingman A, Elder P, Blum W, KlisoviC R, Penza S, Andritsos LA, Benson DM, Efebera Y, Hofineister CC, Garzon R, MarcuccI G, Devine SM. "Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S320-S321.

Paul Gerard Guy Richardson, Craig C. Hofmeister, David Samuel DiCapua Siegel, Sagar Lonial, Jacob Laubach, Yvonne Adeduni Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Noopur S. Raje, Mohamed H. Zaki, Ye Hua, Sheetal Shah, Jianming Wang, and Kenneth Carl Anderson. "MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)." In Journal of Clinical Oncology. (May 2013). Abstract #8584-.

Bradley M. Haverkos, Ali McBride, Kathryn M Leininger, Leslie a. Andritsos, Steven M Devine, Yvonne A Efebera. "Tocilizumab In The Treatment Of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience." In Blood. (November 2013). abstract 2067-.

Julianna V.F. Roddy, Bradley M. Haverkos, Ali McBride, Kathryn M. Leininger, Leslie A. Andritsos, Steven M. Devine, Yvonne A. Efebera. "Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Blood." In Blood. (November 2013). 2067-.

Yvonne Efebera, Parvathi Ranganathan, Xueyan Yu, Jessica Hofstetter, Sabrina Garman, Laura Gibson, William Petros, Michael Criag, Cecilia Fernandez-Cymering, Mehdi Hamadani, Guido Marcucci, Steven Devine, Muller Fabbri and Ramiro Garzon.. "Serum miR-29a is up-regulated in acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo HSCT) and activates dendritic cells (DCs)." In Blood. (November 2013). abstract 4471-.

Flavia Pichiorri, Alberto Rocci, Craig C Hofmeister, Susan Geyer, Tiffany Talabere, Massimiliano Gambella, Luciano Cascione, Andrew Stiff, Don M. Benson Jr., Yvonne A Efebera, Vijaya Dirisala, Emily M Smith, Paola Omedè, Pellegrino Musto, Davide Rossi, Silvia Gentili, Giuseppina Uccello, Roberto Ria, Giulia Benevolo, Sara Bringhen, Vincenzo Callea, Brendan M Weiss, Alfredo Ferro, Valeria Magarotto, Hansjuerg Alder, John C. Byrd, Mario Boccadoro, Guido Marcucci, Antonio Palumbo.. ". Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma." In Blood. (October 2013). abstract 1853-.

Yvonne A. Efebera, Susan Geyer, Anissa Bingman, Rhonda Kitzler, Patrick Elder, Carrie Hennelly, Leslie Andritsos, Samantha Jaglowski, William Blum, Rebecca Klisovic, Sam Penza, Sumithira Vasu, Craig C.Hofmeister, Don M. Benson, Steven M. Devine, Gerard Lozanski. "Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S202-S202, abstract 178.

Akshata Pandit, Lai Wei, Patrick Elder, William Falk, Megan Sell, MS, Craig C. Hofmeister, Don M. Benson, Sam Penza, Leslie Andritsos, Rebecca Klisovic, Sumithira Vasu, William Blum, Steven M. Devine, Samantha Jaglowski, Yvonne A. Efebera. "Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S186-S186, abstract 145.

Galena Salem, Amy S. Ruppert, Patrick Elder, Craig C.Hofmeister, Don M. Benson, Sam Penza, Leslie Andritsos, Rebecca Klisovic, Sumithira Vasu, William Blum, Steven M Devine, Samantha Jaglowski, Yvonne A. Efebera. "Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S304-S305, abstract 391.

Paul G. Richardson, Craig C. Hofmeister, Noopur S. Raje, David S. Siegel, Sagar Lonial, Jacob Laubach, Yvonne A. Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Mohamed H. Zaki, Ye Hua, Yan Li, Sheetal Shah, Jianming Wang, Kenneth C. Anderson. "Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) in Lenalidomide-Refractory and Proteasome Inhibitor-Exposed Myeloma: The Phase 1 MM-005 Trial." In Hematologica. (June 2013). 97-8 Abstract 226.

Benjamin Chu, Megan Sell, Jill Tucker, Arwa Shana' ah, Craig C. Hofmeister, Flavia Pichiorri, Don M. Benson, Yvonne A. Efebera.. "Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome." 14th International Myeloma Workshop. .

 

Degrees

1994 B.S., University of The District of Columbia

1998 M.D., The Pennsylvania State University College of Medicine

 

Editorial Activities

2010 - present Bone Marrow Transplant
2010 - present Biology of Blood and Marrow Transplantation
2014 - present Blood Journal
 

Honors

1990 - 1994 Dean's List.
1991 - present The William Curtis Award for Outstanding Junior in Chemistry. ..
1991 - 1994 Participant of the Honors Undergraduate Research Training Program. NIH-MARC (National Institute of Health-Minority Access to Research Careers).
1991 - 1994 Beta Kappa Chi National Scientific Honor Society.
1994 The American Chemical Society award for best graduating senior in Chemistry. The American Chemical Society.
2007 - present VA Boston Healthcare System Golden Heart Award for Outstanding Service. VA Boston Healthcare System.
2009 - 2013 K12 Translational Training Grant in Experimental Therapeutics. National Institute of Health (NIH).
2011 - present West Virginia WVCTSI Ohio State CCTS Partnership Pilot Award. West Virginia WVCTSI.
 

Journal Articles

Szymanska G, Stromer H, Silverman M, Belu-John YA, Morgan JP. "Altered Phosphorylation of Sarcoplasmic Reticulum Contributes to the Diminished Contractile Response to Isoproteronol in Hypertrophied Rat Hearts." European Journal of Physiology. Vol. 439, no. 1-2. (January 1999.): 1-10.

Ahmadi T, Flies A, Efebera YA, Sherr DH. "CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides." Immunology. Vol. 124, no. 1. (May 2008.): 129-140.

Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A, Hosing C, Ledford M, Champlin R, Giralt S. "Impact of pre-stem cell transplant Ferritin levels on late transplant complications. A landmark analysis to determine potential role of iron chelation in improving transplant Outcomes." Biology of Blood and Marrow Transplantation. Vol. 15, no. 2. (February 2009.): 92-93.

de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. "Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation." Biol Blood Marrow Transplant. Vol. 15, no. 9. (September 2009.): 1094-1099.

Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody." Blood. Vol. 116, no. 13. (September 2010.): 2286-2294.

Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. "The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes.." Internet J Hematology. Vol. 7, no. 1. (January 2010.): .-.

Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. "Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma." Biol Blood Marrow Transplant. Vol. 16, no. 8. (August 2010.): 1122-1129.

Benson DM, Bakan CE, Shuhong Z, Collins SM, Liang J, Shivani S, Hofmeister CC, Efebera Y, Pascale A, Francois R, Blery M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. "IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect." Blood. Vol. 118, no. 24. (December 2011.): 6387-6391.

Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T. "Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing." AM J Surg Pathol. Vol. 35, no. 11. (November 2011.): 1685-1690.

Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." HEMATOLOGICAL ONCOLOGY. Vol. 29, no. 4. (December 2011.): 202-210.

Efebera,YA. "Necrobiotic xanthogranuloma.." Clin Adv Hematol Oncol. Vol. 9, no. 9. (September 2011.): 700-701.

Efebera YA, Blanchard E, Allam C, Han A, Lee S, Munshi N. "Complete Response to Thalidomide and Dexamethasone in a Patient With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathy: A Case Report and Review of the Literature." Clinical Lymphoma Myeloma and Leukemia. Vol. 11, no. 3. (June 2011.): 298-302.

Crawford MS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.. "Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.." HEMATOLOGICAL ONCOLOGY. Vol. 30, no. 3. (September 2012.): 156-162.

Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. "A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma." Blood. Vol. 120, no. 22. (November 2012.): 4324-4333.

Dunavin NC, Wei L, Elder P, Phillips G, Benson DM Jr., Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA.. "Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma." Blood. Vol. 54, no. 8. (August 2013.): 1658-64.

Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. "Characterization of multiple myeloma vesicles by label-free relative quantitation.." Proteomics. Vol. 13, no. 20. (October 2013.): 3013-3029.

Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr. "Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.." Cancer Immunol Immunother. Vol. 62, no. 12. (December 2013.): 1841-9.

Ferreira L, Efebera Y, Allen CM. "CLINICAL PATHOLOGIC CONFERENCE CASE 2: A DIFFUSE SWELLING OF THE NECK." ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY. Vol. 115, no. 5. (May 2013.): E36-E40.

Efebera YA, Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio D. "Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred." Amyloid. Vol. early release, (March 2014.): n/a-.

Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. "A phase I trial of flavopiridol in relapsed multiple myeloma." Cancer Chemother Pharmacol. Vol. 73, no. 2. (February 2014.): 249-57.

 

Presentations

"MGUS and Multiple Myeloma: Review." Boston, MA. (April 2005)

"Colorectal Cancer." Boston, MA. (June 2006)

"ASCO Review 2006: Lung Cancer." Presented at Boston University Grand Rounds, Boston. (June 2006)

"CD40 Ligand Alters B cell Migration to Secondary Lymphoid Organs- Potential for B cells as APC in Vaccine Immunotherapy." Presented at Boston University Annual Research Project, Boston, MA. (September 2006)

"Boston University weekly Tumor Board." Boston, MA. (January 2006)

"Acute Promyelocytic Leukemia. Management." Boston, MA. (January 2007)

"Neoadjuvant Therapy in Locally Advanced Breast Cancer." Boston, MA. (April 2007)

"Waldenström Macroglobulinemia: a Review." Boston, MA. (June 2007)

"ASCO Review 2007: Metastatic Breast Cancer." Presented at Boston University Grand Rounds, Boston, MA. (June 2007)

"Fatal Hepatitis B infection: Reactivation vs De. Novo in a patient with CLL." Boston, MA. (August 2007)

"Esthesioneuroblastoma: Case report, Clinical presentation and management." Boston, MA. (August 2007)

"A Patient with HIT with elevated platelets." Boston, MA. (October 2007)

"Myelofibrosis and Angiodysplasia: Case Report and Review of Management.." Boston, MA. (March 2007)

"AL Amyloidosis: Case report and Review of the Literature." Boston, MA. (November 2007)

"High- Dose Melphalan vs Melphalan + Dexamethasone for AL Amyloidosis." . (September 2007)

"Systemic Chemotherapy and Management of Metastatic Melanoma." Boston, MA. (February 2007)

"Posaconazole vs Fluconazole prophylaxis in allogeneic Stem Cell Transplant patients with GVHD." Boston, MA. (February 2007)

"Management of Adrenal Carcinoma: Case Report and Review of the Literature." Boston, MA. (February 2007)

"HIV Lymphoma and Autologous Stem Cell Transplantation: Review of the literature." Boston, MA. (February 2007)

"Extragonadal Germ Cell Tumor. Case Report and Review of the Literature." Boston, MA. (July 2007)

"Bronchial Carcinoid: Case Report and Review of the Literature." Boston, MA. (December 2007)

"Lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk Myelodysplastic syndromes with karyotypes other than deletion 5q." Presented at Monthly Journal Club, Boston. (January 2008)

"Diagnosis and Management of ALL: Case Report and Review of the Literature.." Boston, MA. (January 2008)

"Highlights in Hematology." Presented at ASCO Review, Columbus, OH, US|USA. (June 2010)

"Update on Primary Amyloidosis." Presented at Amyloid Support Group, Columbus. (April 2010)

"Update on Multiple Myeloma and Treatment." Presented at Myeloma Support Group, Columbus. (September 2010)

"American Society of Hematology Review - on multiple Myeloma, Amyloidosis and Transplant." Presented at American Society of Hematology Review, Columbus. (January 2011)

"Myeloma Update." Presented at Lymphoma / Leukemia Meeting, Cincinnati, Ohio. (February 2011)

"OSU Fellows Board Review." Presented at OSU Fellows Board Review, Columbus. (January 2011)

"Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome." Presented at 14th International Myeloma Workshop, Kyoto, JP|JPN. (April 2013)

"American Society of Hematology Oral Abstract Session." Presented at 55th Annual American Society for Hematology (ASH) Conference, . (December 2013)

 

Professional Activities

2009 - present MMORE. Multiple Myelomia Opprotunities for Research and Education. Columbus, OH.
 

Unpublished Works

Salem G, Ruppert AS, Elder P, Hofmeister, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA.. Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant ( allo HSCT).. March 2014.

Roddy JVF, Haverkos BM, McBride A, Leininger KM, Andritsos LA, Devine SM, Efebera YA.. Tocilizumab for steroid refractory Acute Graft versus Host Disease. March 2014.

Chu B, Sell M, Tucker J, Shana' ah A, Hofmeister CC, Pichiorri F, Benson, DM Jr, Efebera YA. Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome.. March 2014.